• Revenue up 44% to $25.5M, driven by new sales and full period impact of prior year contracts
• Profit after tax of $1.3M, a significant turnaround from prior year loss
• Underlying EBITDA increased 675% to $4.2M

Alcidion Group Limited reported a strong first half performance for the period ended 31 December 2025, with revenue increasing 44% to $25.5M and a significant turnaround to profitability, delivering $1.3M in profit after tax compared to a $889k loss in the prior corresponding period. The revenue increase was driven by continued momentum from new sales such as the NCIC Mizaic and Leidos expansion contracts, as well as the full six-month impact of the NCIC EPR contract and Hywel Dda Health Board recurring and services revenue. Underlying EBITDA increased 675% to $4.2M as the business maintained tight cost control. The company also highlighted significant new contract wins and renewals during the period, including a $6.8M contract expansion with NCIC and a $12.3M contract expansion with Leidos Australia. Subsequent to the period end, Alcidion was selected as the preferred EPR supplier by University Hospitals Sussex NHS Foundation Trust, with a total contract value expected to exceed $35M over a minimum 7-year period.

Building on the strong first half performance, full year FY26 EBITDA and cash flow are expected to be at least in line with FY25, with potential upside dependent on the successful completion of the University Hospitals Sussex contract and continued conversion of new revenue opportunities.

Alcidion is targeting deployment commencement of the University Hospitals Sussex EPR contract in Q4 FY26. The company expects to continue its strong growth trajectory, with the potential for further new contract wins and renewals over the course of the second half of the financial year.